Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer
The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of HRS-4357 injection in adult patients with advanced prostate cancer.
Advanced Prostate Cancer
DRUG: HRS-4357 injection
Prog Dose limiting toxicity (DLT), up to 9 months follow-up|recommended phase 2 dose (RP2D), up to 9 months follow-up|recommended dosing cycle., up to 9 months follow-up|PSA50 response rate, up to 12 weeks follow-up
Maximum plasma concentration (Cmax), up to 6 weeks follow-up|time to maximum plasma concentration (Tmax), up to 6 weeks follow-up|area under the plasma concentration-time curve (AUC), up to 6 weeks follow-up|clearance (Cl), up to 6 weeks follow-up|volume of distribution (Vz), up to 6 weeks follow-up|terminal half-life (t1/2), up to 6 weeks follow-up|cumulative urinary excretion of radioactive dose, up to 6 weeks follow-up|Absorbed dose and effective dose of radioactive internal irradiation of the whole body and major organs;, up to 6 weeks follow-up|PSA90 response rate, up to 12 weeks follow-up]|time to PSA progression, up to 9 months follow-up|Overall Response Rate (ORR), up to 20 months follow-up|Disease control Rate (DCR), up to 20 months follow-up|Duration of Response (DoR), up to 20 months follow-up|Radiographic Progression-free Survival (rPFS), up to 9 months follow-up|Overall Survival (OS), up to 20 months follow-up|Incidence and severity of AEs and SAEs, up to 20 months follow-up
The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of HRS-4357 injection in adult patients with advanced prostate cancer.